0001143313-23-000179.txt : 20231129
0001143313-23-000179.hdr.sgml : 20231129
20231129111014
ACCESSION NUMBER: 0001143313-23-000179
CONFORMED SUBMISSION TYPE: 25-NSE
PUBLIC DOCUMENT COUNT: 2
FILED AS OF DATE: 20231129
DATE AS OF CHANGE: 20231129
EFFECTIVENESS DATE: 20231129
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: Timber Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001504167
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 593843182
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 25-NSE
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37411
FILM NUMBER: 231449655
BUSINESS ADDRESS:
STREET 1: 3 MOUNTAINVIEW ROAD, SUITE 100
CITY: WARREN
STATE: NJ
ZIP: 07059
BUSINESS PHONE: (917) 697-3130
MAIL ADDRESS:
STREET 1: 3 MOUNTAINVIEW ROAD, SUITE 100
CITY: WARREN
STATE: NJ
ZIP: 07059
FORMER COMPANY:
FORMER CONFORMED NAME: BioPharmX Corp
DATE OF NAME CHANGE: 20140304
FORMER COMPANY:
FORMER CONFORMED NAME: THOMPSON DESIGNS INC
DATE OF NAME CHANGE: 20101022
FILED BY:
COMPANY DATA:
COMPANY CONFORMED NAME: NYSE AMERICAN LLC
CENTRAL INDEX KEY: 0001143313
IRS NUMBER: 522127241
FILING VALUES:
FORM TYPE: 25-NSE
BUSINESS ADDRESS:
STREET 1: 11 Wall Street
CITY: New York
STATE: NY
ZIP: 10005
BUSINESS PHONE: 212-656-5414
MAIL ADDRESS:
STREET 1: 11 Wall Street
CITY: New York
STATE: NY
ZIP: 10005
FORMER COMPANY:
FORMER CONFORMED NAME: NYSE MKT LLC
DATE OF NAME CHANGE: 20120514
FORMER COMPANY:
FORMER CONFORMED NAME: NYSE Amex
DATE OF NAME CHANGE: 20090402
FORMER COMPANY:
FORMER CONFORMED NAME: NYSE Alternext US LLC
DATE OF NAME CHANGE: 20081009
25-NSE
1
primary_doc.xml
X0203
0001143313
NYSE AMERICAN LLC
0001504167
Timber Pharmaceuticals, Inc.
001-37411
1098 Hamilton Court
Menlo Park
CA
CALIFORNIA
94025
(650) 889-5020
Common Stock
17 CFR 240.12d2-2(b)
Emily Fuhrman
Analyst, Regulation
2023-11-29
EX-99.25
2
ruleprovisionnotice.htm
NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES
NYSE American LLC ("NYSE American" or the "Exchange") hereby notifies the Securities and Exchange Commission (the "Commission") of its intention to remove the Common Stock of Timber Pharmaceuticals, Inc. (the "Company") from listing and registration on the Exchange at the opening of business on December 11, 2023, pursuant to the provisions of Rule 12d2-2(b) because, in the opinion of the Exchange, the Common Stock is no longer suitable for continued listing and trading on the Exchange.
The Exchange determined that the Company is no longer suitable for listing pursuant to Section 1003(c)(iii) of the NYSE American Company Guide in light of the Company's Form 8-K disclosure on November 17, 2023 that the Company and certain of its affiliates filed voluntary petitions for relief under Chapter 11 of Title 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware. The Exchange noted that the Company's Form 8-K discloses that holders of shares of the Company's common stock could experience a complete loss on their investment.
On November 21, 2023, the Exchange determined that the Common Stock should be suspended from trading and directed the preparation and filing with the Commission of this application for the removal of the Common Stock from listing and registration on the NYSE American. The Company was notified on November 21, 2023.
The Company had a right to appeal to a Committee of the Board of Directors of the Exchange (the "Committee") the determination to delist the Common Stock, provided it filed a written request for such a review with the Secretary of the Exchange within seven calendar days of receiving notice of the delisting determination. The Company infomed that Exchange on November 28, 2023 that it will not excersie that right. Consequently, all conditions precedent under SEC Rule 12d2-2(b) to the filing of this application have been satisfied.